Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chemotherapy regimen-Institute of Hematology & Blood Diseases Hospital, China-acute lymphoblastic leukemia
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral, Intramuscular, Subcutaneous
01
Overview
This multi-agent chemotherapy regimen is a standardized treatment protocol developed by the Institute of Hematology & Blood Diseases Hospital, China, for the management of acute lymphoblastic leukemia (ALL). It consists of a combination of cytotoxic agents and glucocorticoids, including vincristine, prednisone, daunorubicin, cyclophosphamide, pegaspargase, cytarabine, mercaptopurine (6-MP), methotrexate (MTX), and dexamethasone. The regimen operates through multiple mechanisms: vincristine disrupts microtubule formation; daunorubicin and cyclophosphamide damage DNA; pegaspargase depletes L-asparagine; cytarabine, mercaptopurine, and methotrexate inhibit various stages of nucleic acid synthesis; and prednisone and dexamethasone induce lymphocytolysis. In clinical research, this regimen serves as a foundational backbone for evaluating novel targeted therapies, such as olverembatinib, ruxolitinib, and venetoclax, particularly in high-risk subgroups like Ph-like ALL.
- Other names
- Chemotherapy Regimen (Institute of Hematology & Blood Diseases Hospital)Multi-agent chemotherapy for ALLvincristine + prednisone + daunorubicin + cyclophosphamide + pegaspargase + cytarabine + mercaptopurine + methotrexate + dexamethasone
02
Targets
DHFR (Dihydrofolate reductase)TOP2A (DNA topoisomerase II)DNA polymerase familyDNATUBB (Tubulin (alpha and beta subunits))PPAT (Amidophosphoribosyltransferase)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on chemotherapy regimen-Institute of Hematology & Blood Diseases Hospital, China-acute lymphoblastic leukemia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chemotherapy regimen-Institute of Hematology & Blood Diseases Hospital, China-acute lymphoblastic leukemia.